1993P A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 35; p. S1153
Main Authors D'Souza, A.A., Mar, N., Parikh, R., Parikh, M., Arora, M., Hinton, S., Lyou, Y.M., Ohr, J., Peracha, S., Sadeghi, S., Sulecki, M., Thomas, R.A., Villalona-Calero, M., Lara, P.N., Sharon, E., Krailo, M., Quinn, D.I.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2024
Online AccessGet full text

Cover

Author Parikh, M.
Sharon, E.
Sadeghi, S.
Thomas, R.A.
Villalona-Calero, M.
Lara, P.N.
Quinn, D.I.
Ohr, J.
Peracha, S.
D'Souza, A.A.
Parikh, R.
Arora, M.
Hinton, S.
Mar, N.
Sulecki, M.
Krailo, M.
Lyou, Y.M.
Author_xml – sequence: 1
  givenname: A.A.
  surname: D'Souza
  fullname: D'Souza, A.A.
  organization: Medicine Department, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
– sequence: 2
  givenname: N.
  surname: Mar
  fullname: Mar, N.
  organization: Hematology/Oncology Department, UCI Health - University of California Irvine, Orange, CA, USA
– sequence: 3
  givenname: R.
  surname: Parikh
  fullname: Parikh, R.
  organization: Hematology/Oncology Department, KUMC - University of Kansas Medical Center, Kansas City, KS, USA
– sequence: 4
  givenname: M.
  surname: Parikh
  fullname: Parikh, M.
  organization: Hematology/Oncology Department, University of California Davis, Sacramento, CA, USA
– sequence: 5
  givenname: M.
  surname: Arora
  fullname: Arora, M.
  organization: Hematology/Oncology /Internal Medicine Dept., UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
– sequence: 6
  givenname: S.
  surname: Hinton
  fullname: Hinton, S.
  organization: Hematology/Oncology Department, KUMC - University of Kansas Medical Center, Kansas City, KS, USA
– sequence: 7
  givenname: Y.M.
  surname: Lyou
  fullname: Lyou, Y.M.
  organization: Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
– sequence: 8
  givenname: J.
  surname: Ohr
  fullname: Ohr, J.
  organization: Hematology/Oncology Department, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
– sequence: 9
  givenname: S.
  surname: Peracha
  fullname: Peracha, S.
  organization: Oncology Department, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
– sequence: 10
  givenname: S.
  surname: Sadeghi
  fullname: Sadeghi, S.
  organization: Medicine Department, USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, CA, USA
– sequence: 11
  givenname: M.
  surname: Sulecki
  fullname: Sulecki, M.
  organization: Hematology/Oncology Department, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA
– sequence: 12
  givenname: R.A.
  surname: Thomas
  fullname: Thomas, R.A.
  organization: Hematology/Oncology Department, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
– sequence: 13
  givenname: M.
  surname: Villalona-Calero
  fullname: Villalona-Calero, M.
  organization: Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA
– sequence: 14
  givenname: P.N.
  surname: Lara
  fullname: Lara, P.N.
  organization: Hematology-Oncology, Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
– sequence: 15
  givenname: E.
  surname: Sharon
  fullname: Sharon, E.
  organization: Division of Cancer Treatment & Diagnosis, National Cancer Institute, Bethesda, MD, USA
– sequence: 16
  givenname: M.
  surname: Krailo
  fullname: Krailo, M.
  organization: Research Population and Public Health Sciences, Keck School of Medicine - University of Southern California USC, Los Angeles, CA, USA
– sequence: 17
  givenname: D.I.
  surname: Quinn
  fullname: Quinn, D.I.
  organization: Translation and Clinical Science Program / Oncology Division, USC - University of Southern California - Keck School of Medicine, Los Angeles, CA, USA
BookMark eNqFUcFq3DAQdSGFJmk_oTAfUG9lW_auTyWENl0IJIf2bMbyiNUiS0aSN-x-fUdsLz31NGJGb9578-6KG-cdFcXnSmwqUXVfjxt03FKbWtRyI3Zct_1NcSv6uim3bSM_FHcxHoUQXV_3t--g6vvmFR4goJv8bC40fYHlgJFgv4cUDFpIHuiEdsVEkA4EETWlMzAASGujUJ3Ba6BgxtUaBzPFs82f-a38PBqHyXgHbyYdgPsXb81lnXHM0wUDTZninwFatpXxcR2PpFK8gq1XaC1TTyd0inE-MFvCmJhBsVx00WQuVq3IWliDZ8U2u1AZEeDtQIFAmbiwROPKka0yfyBMM7kEJoLzic2BX_Kmj8V7jTbSp7_1vvj94_uvx5_l88vT_vHhuVSVqPtSth12k0TZKt3IZkS501ul2kpOHY16rCXVvSBdNyMH0213QnJPi74j2aOomvuive5VwccYSA9LMDOG81CJIUc7HIdrtEOOdhC7IUfLuG9XHLG4k6EwRGUoH8cEPtwwefOfDX8Aeaa7Bg
ContentType Journal Article
Copyright 2024
Copyright_xml – notice: 2024
DBID AAYXX
CITATION
DOI 10.1016/j.annonc.2024.08.2079
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage S1153
ExternalDocumentID 10_1016_j_annonc_2024_08_2079
S0923753424035981
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
0U7
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6J9
70D
AAEDW
AAJKP
AAJQQ
AAKAS
AAKUH
AALRI
AAMVS
AAOGV
AAPNW
AAUQX
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABQTQ
ABSAR
ABSMQ
ABVKL
ABZBJ
ACGFO
ACGFS
ACMRT
ACPQN
ACPRK
ACUFI
ACUTO
ADBBV
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADRIX
ADRTK
ADVLN
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFETI
AFIYH
AFJKZ
AFOFC
AFSHK
AFXEN
AGINJ
AGKEF
AGKRT
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
AQKUS
ASPBG
ATTQO
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BGNMA
BHONS
BTRTY
BVRKM
BZKNY
C1A
CAG
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DL5
D~K
E3Z
EBS
EE~
EJD
EX3
F9B
FDB
FEDTE
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
I09
IH2
IHE
IOX
J21
KAQDR
KDC
KOM
KOP
KQ8
KSI
KSN
LAK
M-Z
M41
M49
M4Y
MBLQV
MHKGH
N9A
NCXOZ
NGC
NOYVH
NTWIH
NU-
NU0
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RPX
RW1
RXO
RZC
RZE
RZF
RZO
SDH
TCURE
TEORI
TJX
TMA
TR2
U2A
W8F
WOQ
WOW
X7H
YAYTL
YFH
YKOAZ
ZKX
ZXP
~91
AAGQS
AAYWO
AAYXX
ABNGD
ACUKT
ACVFH
ADCNI
AEUPX
AFPUW
AGCQF
AGQPQ
AIGII
AKBMS
AKYEP
APXCP
CITATION
ID FETCH-LOGICAL-c1029-456a6d4a45cf343ba48f7cc514d6ebfb24e290ef23b02467804b24f096e49a013
ISSN 0923-7534
IngestDate Tue Jul 01 00:28:55 EDT 2025
Sat Nov 02 16:00:47 EDT 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1029-456a6d4a45cf343ba48f7cc514d6ebfb24e290ef23b02467804b24f096e49a013
ParticipantIDs crossref_primary_10_1016_j_annonc_2024_08_2079
elsevier_sciencedirect_doi_10_1016_j_annonc_2024_08_2079
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2024
2024-09-00
PublicationDateYYYYMMDD 2024-09-01
PublicationDate_xml – month: 09
  year: 2024
  text: September 2024
PublicationDecade 2020
PublicationTitle Annals of oncology
PublicationYear 2024
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0006929
Score 2.4539263
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage S1153
Title 1993P A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
URI https://dx.doi.org/10.1016/j.annonc.2024.08.2079
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Zb9NAEIeX0kqIF8QpyjkP8BRsEp_xY8ShhioI9RB9s3bXa9UhsSM7Fmr-ema8vtJGCPoSOXY2a2s-e2fHv5ll7N0wtqVQaIERPiENx7OkwePIM2IpI4V3n1Ie5Q7PvntH5863C_di7-7bnmqpXAtTbnbmldzGqrgP7UpZsv9h2fZPcQduo33xEy2Mn_9kY5LF_cBbG8ebKFsmGx24XF3iyDSYTgd6RQ50LuuS3qryMgsek0yTAuaK6kfQeu_oMSoqIUKq9KUqrhb0Y61Qx5mzZkRnwa3VJlskm3LJRadfxy62DvBFpouRFKWYV3KRqnE1bi6uOt1BltMK1pySmhJJq1WkWkFGNUsopljmlB-2oKuQ1CIf_EbE1EAmxYo0fKlBg3DUU8snxSDNSDQ_yFYtcjdqRWep3Hqb8Pm95Z9m5UbHmM2J2cXpc52O1r1py5NfVSTqZMe-mdkPolhOqxKrI3tNdk8npapCpJZt4HTO6Y8Wttt73ONYoEsd175D-_3GwKRjJHOTpyleo0nnQKVjraFeSudaze9T6pp6pmqJbkClBQ4snAfhg_xgcnzy87h1NrzA0uUk61PtktQ-7uxst_vVc6nOHrIH9VwIJhrsR2xPpY_ZvVmt9nhyByq-YQId3x-gohumU6johnUGDd2ArICmG7ABNHRDFkNDNzR0A2736AYCFPoQQ0M3dbF1oKKb2jd068Y13dDQDVkOHd3QpxuIbujoBk03VHTDNbqhpRuSApBuvDjQdD9l51-_nH06MuoVTQw5Ip0Zzla4FznccWVsO7bgzjj2pcRJS-QpEQvLUVYwVLFlC7SZR8XBcF88DDzlBBxna8_YPppUPWcwUsq1Pd8PfKEcPhJ8HPn-OHYFFcy0A_eQmY2hw5UuXBM2is55qMkIiYxwOA6JjEM2bnAIa-9be9UhMvz3pi9u3_Qlu9_dj6_Y_jov1Wt089fiTY36H6swDF8
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=1993P+A+randomized%2C+phase+II+trial+to+evaluate+the+safety+and+efficacy+of+eribulin+mesylate+in+combination+with+atezolizumab+compared+to+atezolizumab+alone+in+subjects+with+locally+advanced+or+metastatic+transitional+cell+urothelial+cancer+where+cisplatin-based+treatment+is+not+an+option&rft.jtitle=Annals+of+oncology&rft.au=D%27Souza%2C+A.A.&rft.au=Mar%2C+N.&rft.au=Parikh%2C+R.&rft.au=Parikh%2C+M.&rft.date=2024-09-01&rft.pub=Elsevier+Ltd&rft.issn=0923-7534&rft.volume=35&rft.spage=S1153&rft.epage=S1153&rft_id=info:doi/10.1016%2Fj.annonc.2024.08.2079&rft.externalDocID=S0923753424035981
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon